Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide
- PMID: 2045142
- DOI: 10.1161/01.hyp.17.6.798
Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide
Abstract
When the function of the renin system is inhibited, blood pressure becomes more dependent on changes in sodium and water balance. Diuretics alone and sodium restriction alone are additive to converting enzyme inhibitor therapy. However, it is not known if these two ways of reducing sodium balance are additive in the presence of established converting enzyme inhibition. We therefore performed a double-blind crossover study of the effects of moderate sodium restriction in 21 patients with essential hypertension who were already being treated with the combination of a converting enzyme inhibitor and a diuretic. After 1 month of captopril (50 mg twice daily) and hydrochlorothiazide (25 mg once daily) therapy, with their usual sodium intake, average supine blood pressure was 147/96 +/- 5/3 (SEM) mm Hg 2 hours after treatment. Patients then reduced their sodium intake to around 80-100 mmol/day for the remainder of the study. After 2 weeks of sodium restriction, they entered a double-blind, randomized, crossover study of Slow Sodium (100 mmol sodium/day) compared with Slow Sodium placebo, while continuing sodium restriction and the above treatment. During the double-blind study, after 1 month of treatment with captopril (50 mg twice daily), hydrochlorothiazide (25 mg once daily), and Slow Sodium placebo, supine blood pressure 2 hours after treatment was 138/88 +/- 4/2 mm Hg (24-hour urinary sodium 104 +/- 11 mmol). After 1 month of captopril (50 mg twice daily), hydrochlorothiazide (25 mg once daily), and Slow Sodium tablets, supine blood pressure 2 hours after treatment was 147/91 +/- 5/2 mm Hg (p less than 0.05; 24-hour urinary sodium 195 +/- 14 mmol).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide.Hypertension. 1995 May;25(5):1042-4. doi: 10.1161/01.hyp.25.5.1042. Hypertension. 1995. PMID: 7737713 Clinical Trial.
-
Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study.Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):531-4. doi: 10.1136/bmj.294.6571.531. Br Med J (Clin Res Ed). 1987. PMID: 3103761 Free PMC article. Clinical Trial.
-
Moderate sodium restriction, angiotensin converting enzyme inhibition, and thiazide diuretic in the management of essential hypertension.J Cardiovasc Pharmacol. 1989;13 Suppl 3:S5-7. doi: 10.1097/00005344-198900133-00003. J Cardiovasc Pharmacol. 1989. PMID: 2474103 Clinical Trial.
-
Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.Adv Ther. 2017 Apr;34(4):784-798. doi: 10.1007/s12325-017-0497-8. Epub 2017 Mar 4. Adv Ther. 2017. PMID: 28260186 Free PMC article. Review.
-
Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction.Curr Clin Pharmacol. 2019;14(1):5-15. doi: 10.2174/1574884713666181025145404. Curr Clin Pharmacol. 2019. PMID: 30360726 Review.
Cited by
-
Individualised selection of antihypertensive therapy.Drugs. 1993;46 Suppl 2:142-8. doi: 10.2165/00003495-199300462-00023. Drugs. 1993. PMID: 7512467 Review.
-
Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials.BMJ. 2020 Feb 24;368:m315. doi: 10.1136/bmj.m315. BMJ. 2020. PMID: 32094151 Free PMC article.
-
Use of diuretics in cardiovascular disease: (2) hypertension.Postgrad Med J. 2004 May;80(943):271-6. doi: 10.1136/pgmj.2003.010843. Postgrad Med J. 2004. PMID: 15138316 Free PMC article. Review.
-
Management of Hypertension in Patients with Chronic Kidney Disease.Curr Hypertens Rep. 2017 May;19(5):43. doi: 10.1007/s11906-017-0739-9. Curr Hypertens Rep. 2017. PMID: 28451853 Review.
-
Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials.J Clin Hypertens (Greenwich). 2018 Jan;20(1):136-142. doi: 10.1111/jch.13151. Epub 2017 Dec 18. J Clin Hypertens (Greenwich). 2018. PMID: 29265730 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical